Keita Shibata, Terumasa Hashimoto, Takuro Miyazaki*, Akira Miyazaki and Koji Nobe Pages 242 - 250 ( 9 )
Background: Thromboembolic ischemic stroke, which is mainly caused by hypertension, as well as plasma dyslipidemia, arterial fibrillation and diabetes, is a leading cause of death in the US and other countries. Numerous clinical trials for thrombolytic drugs, which aimed to pharmacologically dissolve thrombi, were conducted in the 1950s, when the first thrombolytic therapy was performed.
Methods: In this study, we summarize the pathophysiologic features of ischemic stroke, and the history of thrombolytic therapy, and discuss the recent progress that has been made in the ongoing development of thrombolytic drugs.
Conclusion: Thrombolytic therapy is sometimes accompanied by harmful hemorrhagic insults; accordingly, a window of time wherein therapy can safely be performed has been established for this approach. Several basic and clinical studies are ongoing to develop next-generation thrombolytic drugs to expand the time window.
Tissue plasminogen activator, tenecteplase, desmoteplase, SMTP-7, blood-brain barrier, cerebral infarction.
Division of Pharmacology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy, Hatanodai, Shinagawa-ku, Tokyo 142-8555, Division of Pharmacology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy, Hatanodai, Shinagawa-ku, Tokyo 142-8555, Department of Biochemistry, Showa University School of Medicine, Shinagawaku, Tokyo 142-8555, Department of Biochemistry, Showa University School of Medicine, Shinagawaku, Tokyo 142-8555, Division of Pharmacology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy, Hatanodai, Shinagawa-ku, Tokyo 142-8555